Connecticut SB 231: AN ACT CONCERNING WORKERS' COMPENSATION BENEFITS FOR CERTAIN MENTAL OR EMOTIONAL IMPAIRMENTS SUFFERED BY EMERGENCY MEDICAL SERVICES PERSONNEL, DEPARTMENT OF CORRECTION EMPLOYEES AND DISPATCHERS.

Status: Joint Favorable Substitute (as of 2020-03-10)

State: Connecticut · Session: 2020 · Bill: SB 231

Subjects: Correctional institution employees, Public safety telecommunicators, Workers' compensation, Emergency medical responders

Sponsors: Anwar, Saud, Borer, Dorinda, Boyd, Patrick S., Haskell, Will, Hayes, Rick L., Linehan, Liz, Looney, Martin M., Osten, Catherine A., Porter, Robyn A., Rochelle, Kara, Turco, Gary A., Winkler, Michael A.

Bill Text

LCO 1 of 8

General Assembly Substitute Bill No. 231
February Session, 2026

AN ACT CONCERNING THE DEPARTMENT OF CONSUMER
PROTECTION'S RECOMMENDATIONS REGARDING CANNABIS
REGULATION AND ELECTRONIC NICOTINE DELIVERY SYSTEM
DEALER REGISTRATION.
Be it enacted by the Senate and House of Representatives in General
Assembly convened:

Section 1. Section 21a-408w of the general statutes is repealed and the 1
following is substituted in lieu thereof (Effective from passage): 2
(a) Each cannabis establishment shall submit marijuana samples to a 3
cannabis testing laboratory for testing [as set forth in subsection (b) of 4
this section] in accordance with the laboratory testing standards 5
established in the policies and procedures issued, and final regulations 6
adopted, by the Commissioner of Consumer Protection pursuant to 7
section 21a-421j. 8
[(b) (1) A cannabis testing laboratory shall test each marijuana sample 9
submitted pursuant to subsection (a) of this section (A) for 10
microbiological contaminants, mycotoxins, heavy metals and pesticide 11
chemical residue, and (B) for purposes of conducting an active 12
ingredient analysis, if applicable. 13
(2) Microbiological contaminant testing conducted pursuant to 14
subparagraph (A) of subdivision (1) of this subsection shall include, but 15
not be limited to, microbiological contaminant testing for Aspergillus 16

Raised Bill No. 231

LCO 2 of 8

species as set forth by the Department of Consumer Protection and 17
posted on the department's Internet web site. 18
(c) When conducting microbiological testing as set forth in subsection 19
(b) of this section, the marijuana sample shall be tested by using (1) a 20
molecular method that (A) includes quantitative polymerase chain 21
reaction, (B) is certified for identifying microbiological DNA, and (C) is 22
approved by (i) the Association of Official Analytical Collaboration 23
International, or (ii) a comparable national or international standards 24
organization designated by the Commissioner of Consumer Protection, 25
or (2) an alternative testing method approved by the Department of 26
Consumer Protection and posted on the department's Internet web site.] 27
[(d)] (b) If a marijuana sample [does not pass] fails the testing [set 28
forth in] required under subsection [(b)] (a) of this section, the cannabis 29
establishment that submitted [such] the failing marijuana sample to the 30
cannabis testing laboratory shall, not later than sixty days after the date 31
of such failed testing, either: 32
(1) Repeat the testing [as set forth in subsections] required under 33
subsection (a) [and (b)] of this section on the marijuana batch from 34
which such marijuana sample was taken, in a form and manner 35
approved by the Department of Consumer Protection. If all repeated 36
testing yields satisfactory results, the marijuana batch from which the 37
marijuana samples were taken shall be released for sale; or 38
(2) If such cannabis establishment submits to the Commissioner of 39
Consumer Protection a remediation plan that is sufficient to ensure 40
public health and safety, and the commissioner approves such 41
remediation plan, remediate the marijuana batch from which such 42
marijuana sample was taken and repeat all testing [as set forth in 43
subsections] required under subsection (a) [and (b)] of this section on 44
such remediated marijuana batch, in a form and manner approved by 45
the Department of Consumer Protection. If all repeated testing yields 46
satisfactory results, the marijuana batch from which the marijuana 47
samples were taken shall be released for sale. [; or] 48

Raised Bill No. 231

LCO 3 of 8

[(3)] (c) If [such] a cannabis establishment does not comply with 49
[subdivision (1) or (2) of this] subsection (b) of this section, or if any 50
subsequent laboratory testing does not yield satisfactory results for the 51
testing [set forth in subsections] required under subsection (a) [and (b)] 52
of this section, the cannabis establishment shall dispose of the entire 53
marijuana batch from which the marijuana sample was taken in 54
accordance with procedures established by the Commissioner of 55
Consumer Protection, as published on the Department of Consumer 56
Protection's Internet web site. The cannabis establishment shall 57
complete such disposal not later than sixty days after the later of (1) the 58
date of the failed testing performed pursuant to subsection (a) of this 59
section, (2) the date of the failed repeated testing performed pursuant to 60
subsection (b) of this section, or (3) if no repeated testing is performed 61
pursuant to subsection (b) of this section, expiration of the sixty-day 62
period established in subsection (b) of this section for the performance 63
of such repeated testing. During such sixty-day period, the cannabis 64
establishment may submit a written request to the department, in a form 65
and manner prescribed by the commissioner, to extend such sixty-day 66
period. The com

View Connecticut SB 231 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.